Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru Repercusiones sanitarias y económicas de la vacunación de niñas preadolescentes contra los tipos 16 y 18 del virus del papiloma humano y el tamizaje del cáncer cervicouterino en las mujeres adultas en el Perú
OBJECTIVE: To estimate the benefits, cost-effectiveness (i.e., value for money), and required financial costs (e.g., affordability) of adding human papillomavirus (HPV) vaccination to Peru's cervical cancer screening program. METHODS: Evidence (e.g., coverage, delivery costs) from an HPV vaccin...
Main Authors: | , , , , , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English Spanish Portuguese |
Published: |
Pan American Health Organization
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/48cf2808da324b73b3d5ee4a019758dc |
id |
ftdoajarticles:oai:doaj.org/article:48cf2808da324b73b3d5ee4a019758dc |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:48cf2808da324b73b3d5ee4a019758dc 2023-05-15T15:19:11+02:00 Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru Repercusiones sanitarias y económicas de la vacunación de niñas preadolescentes contra los tipos 16 y 18 del virus del papiloma humano y el tamizaje del cáncer cervicouterino en las mujeres adultas en el Perú Sue J. Goldie Carol Levin N. Rocio Mosqueira-Lovón Jesse Ortendahl Jane Kim Meredith O'Shea Mireia Diaz Sanchez Maria Ana Mendoza Araujo 2012-12-01T00:00:00Z https://doaj.org/article/48cf2808da324b73b3d5ee4a019758dc EN ES PT eng spa por Pan American Health Organization http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892012001400006 https://doaj.org/toc/1020-4989 https://doaj.org/toc/1680-5348 1020-4989 1680-5348 https://doaj.org/article/48cf2808da324b73b3d5ee4a019758dc Revista Panamericana de Salud Pública, Vol 32, Iss 6, Pp 426-434 (2012) Infecciones por papillomavirus neoplasias del cuello uterino vacunas contra papillomavirus vacunación evaluación de costo-efectividad Perú Papillomavirus infections uterine cervical neoplasms papillomavirus vaccines vaccination cost-effectiveness evaluation Peru Medicine R Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2012 ftdoajarticles 2022-12-31T02:13:35Z OBJECTIVE: To estimate the benefits, cost-effectiveness (i.e., value for money), and required financial costs (e.g., affordability) of adding human papillomavirus (HPV) vaccination to Peru's cervical cancer screening program. METHODS: Evidence (e.g., coverage, delivery costs) from an HPV vaccination demonstration project conducted in Peru was combined with epidemiological data in an empirically calibrated mathematical model to assess screening (HPV DNA testing three to five times per lifetime) and HPV vaccination under different cost, coverage, and efficacy assumptions. Model outcomes included lifetime risk of cancer reduction, cancer cases averted, lives saved, average life expectancy gains, short-term financial costs, and discounted long-term economic costs. RESULTS: Status quo low levels of screening (e.g., cytologic screening at 10.0% coverage) reduced lifetime risk of cervical cancer by 11.9%, compared to not screening. Adding vaccination of preadolescent girls at a coverage achieved in the demonstration program (82.0%) produced an additional 46.1% reduction, and would cost less than US$ 500 per year of life saved (YLS) at ~US$ 7/dose or ~US$ 1 300 at ~US$ 20/dose. One year of vaccination was estimated to cost ~US$ 5 million at ~US$ 5/dose or ~US$ 16 million at ~US$ 20/dose, including programmatic costs. Enhanced screening in adult women combined with preadolescent vaccination had incremental cost-effectiveness ratios lower than Peru's 2005 per capita gross domestic product (GDP; US$ 2 852, in 2009 US$), and would be considered cost-effective. CONCLUSIONS: Preadolescent HPV vaccination, followed by enhanced HPV DNA screening in adult women, could prevent two out of three cervical cancer deaths. Several strategies would be considered "good value" for resources invested, provided vaccine prices are low. While financial costs imply substantial immediate investments, the high-value payoff should motivate creative mechanisms for financing and scale-up of delivery programs. OBJETIVO: Calcular los beneficios, la ... Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English Spanish Portuguese |
topic |
Infecciones por papillomavirus neoplasias del cuello uterino vacunas contra papillomavirus vacunación evaluación de costo-efectividad Perú Papillomavirus infections uterine cervical neoplasms papillomavirus vaccines vaccination cost-effectiveness evaluation Peru Medicine R Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
spellingShingle |
Infecciones por papillomavirus neoplasias del cuello uterino vacunas contra papillomavirus vacunación evaluación de costo-efectividad Perú Papillomavirus infections uterine cervical neoplasms papillomavirus vaccines vaccination cost-effectiveness evaluation Peru Medicine R Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Sue J. Goldie Carol Levin N. Rocio Mosqueira-Lovón Jesse Ortendahl Jane Kim Meredith O'Shea Mireia Diaz Sanchez Maria Ana Mendoza Araujo Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru Repercusiones sanitarias y económicas de la vacunación de niñas preadolescentes contra los tipos 16 y 18 del virus del papiloma humano y el tamizaje del cáncer cervicouterino en las mujeres adultas en el Perú |
topic_facet |
Infecciones por papillomavirus neoplasias del cuello uterino vacunas contra papillomavirus vacunación evaluación de costo-efectividad Perú Papillomavirus infections uterine cervical neoplasms papillomavirus vaccines vaccination cost-effectiveness evaluation Peru Medicine R Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
description |
OBJECTIVE: To estimate the benefits, cost-effectiveness (i.e., value for money), and required financial costs (e.g., affordability) of adding human papillomavirus (HPV) vaccination to Peru's cervical cancer screening program. METHODS: Evidence (e.g., coverage, delivery costs) from an HPV vaccination demonstration project conducted in Peru was combined with epidemiological data in an empirically calibrated mathematical model to assess screening (HPV DNA testing three to five times per lifetime) and HPV vaccination under different cost, coverage, and efficacy assumptions. Model outcomes included lifetime risk of cancer reduction, cancer cases averted, lives saved, average life expectancy gains, short-term financial costs, and discounted long-term economic costs. RESULTS: Status quo low levels of screening (e.g., cytologic screening at 10.0% coverage) reduced lifetime risk of cervical cancer by 11.9%, compared to not screening. Adding vaccination of preadolescent girls at a coverage achieved in the demonstration program (82.0%) produced an additional 46.1% reduction, and would cost less than US$ 500 per year of life saved (YLS) at ~US$ 7/dose or ~US$ 1 300 at ~US$ 20/dose. One year of vaccination was estimated to cost ~US$ 5 million at ~US$ 5/dose or ~US$ 16 million at ~US$ 20/dose, including programmatic costs. Enhanced screening in adult women combined with preadolescent vaccination had incremental cost-effectiveness ratios lower than Peru's 2005 per capita gross domestic product (GDP; US$ 2 852, in 2009 US$), and would be considered cost-effective. CONCLUSIONS: Preadolescent HPV vaccination, followed by enhanced HPV DNA screening in adult women, could prevent two out of three cervical cancer deaths. Several strategies would be considered "good value" for resources invested, provided vaccine prices are low. While financial costs imply substantial immediate investments, the high-value payoff should motivate creative mechanisms for financing and scale-up of delivery programs. OBJETIVO: Calcular los beneficios, la ... |
format |
Article in Journal/Newspaper |
author |
Sue J. Goldie Carol Levin N. Rocio Mosqueira-Lovón Jesse Ortendahl Jane Kim Meredith O'Shea Mireia Diaz Sanchez Maria Ana Mendoza Araujo |
author_facet |
Sue J. Goldie Carol Levin N. Rocio Mosqueira-Lovón Jesse Ortendahl Jane Kim Meredith O'Shea Mireia Diaz Sanchez Maria Ana Mendoza Araujo |
author_sort |
Sue J. Goldie |
title |
Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru Repercusiones sanitarias y económicas de la vacunación de niñas preadolescentes contra los tipos 16 y 18 del virus del papiloma humano y el tamizaje del cáncer cervicouterino en las mujeres adultas en el Perú |
title_short |
Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru Repercusiones sanitarias y económicas de la vacunación de niñas preadolescentes contra los tipos 16 y 18 del virus del papiloma humano y el tamizaje del cáncer cervicouterino en las mujeres adultas en el Perú |
title_full |
Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru Repercusiones sanitarias y económicas de la vacunación de niñas preadolescentes contra los tipos 16 y 18 del virus del papiloma humano y el tamizaje del cáncer cervicouterino en las mujeres adultas en el Perú |
title_fullStr |
Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru Repercusiones sanitarias y económicas de la vacunación de niñas preadolescentes contra los tipos 16 y 18 del virus del papiloma humano y el tamizaje del cáncer cervicouterino en las mujeres adultas en el Perú |
title_full_unstemmed |
Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru Repercusiones sanitarias y económicas de la vacunación de niñas preadolescentes contra los tipos 16 y 18 del virus del papiloma humano y el tamizaje del cáncer cervicouterino en las mujeres adultas en el Perú |
title_sort |
health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in peru repercusiones sanitarias y económicas de la vacunación de niñas preadolescentes contra los tipos 16 y 18 del virus del papiloma humano y el tamizaje del cáncer cervicouterino en las mujeres adultas en el perú |
publisher |
Pan American Health Organization |
publishDate |
2012 |
url |
https://doaj.org/article/48cf2808da324b73b3d5ee4a019758dc |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Revista Panamericana de Salud Pública, Vol 32, Iss 6, Pp 426-434 (2012) |
op_relation |
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892012001400006 https://doaj.org/toc/1020-4989 https://doaj.org/toc/1680-5348 1020-4989 1680-5348 https://doaj.org/article/48cf2808da324b73b3d5ee4a019758dc |
_version_ |
1766349357758545920 |